Bulletin
Investor Alert

New York Markets Close in:

Pfizer Inc.

NYS: PFE

GO
/marketstate/country/us

Countdown to close

 --Real time quotes

Apr 20, 2021, 3:43 p.m.

PFE
/zigman2/quotes/202877789/composite

$

39.04

Change

+0.10 +0.27%

Volume

Volume 22.02m

Real time quotes

/zigman2/quotes/202877789/composite

Previous close

$ 38.93

$ 39.04

Change

+0.10 +0.27%

Day low

Day high

$38.75

$39.24

Open

52 week low

52 week high

$29.94

$43.08

Open

Company Description

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commerc...

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Valuation

P/E Current

22.02

P/E Ratio (with extraordinary items)

22.14

P/E Ratio (without extraordinary items)

21.56

Price to Sales Ratio

4.95

Price to Book Ratio

3.24

Price to Cash Flow Ratio

14.39

Enterprise Value to EBITDA

17.05

Enterprise Value to Sales

5.65

Total Debt to Enterprise Value

0.17

Efficiency

Revenue/Employee

533,860.00

Income Per Employee

88,981.00

Receivables Turnover

5.03

Total Asset Turnover

0.26

Liquidity

Current Ratio

1.35

Quick Ratio

1.04

Cash Ratio

0.47

Profitability

Gross Margin

71.21

Operating Margin

21.52

Pretax Margin

17.89

Net Margin

16.67

Return on Assets

4.34

Return on Equity

11.05

Return on Total Capital

8.14

Return on Invested Capital

6.93

Capital Structure

Total Debt to Total Equity

65.26

Total Debt to Total Capital

39.49

Total Debt to Total Assets

26.76

Long-Term Debt to Equity

60.48

Long-Term Debt to Total Capital

36.60

Officers and Executives

Name Age Officer Since Title
Dr. Albert Bourla 58 1993 Chairman, Chief Executive & Operating Officer
Mr. Frank A. D'Amelio 61 2007 Chief Financial Officer & EVP-Business Operations
Dr. Aida Habtezion - - Chief Medical Officer
Dr. Mikael Dolsten 60 2009 President-Bio Therapeutics Research & Development
Ms. Lidia L. Fonseca 50 - Chief Technology Officer & EVP

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
02/27/2021 Frank A. D'Amelio
Executive Vice President
96,872   Derivative/Non-derivative trans. at $34.64 per share. 3,355,646
02/27/2021 Frank A. D'Amelio
Executive Vice President
27,381   Derivative/Non-derivative trans. at $33.49 per share. 916,989
02/27/2021 John D. Young
Group President
82,057   Derivative/Non-derivative trans. at $34.64 per share. 2,842,454
02/27/2021 John D. Young
Group President
23,194   Derivative/Non-derivative trans. at $33.49 per share. 776,767
02/27/2021 Alexander Roderick MacKenzie
Executive Vice President
18,919   Derivative/Non-derivative trans. at $34.64 per share. 655,354
02/27/2021 Alexander Roderick MacKenzie
Executive Vice President
5,812   Derivative/Non-derivative trans. at $33.49 per share. 194,643
02/27/2021 Mikael Dolsten
President R&D
23,841   Derivative/Non-derivative trans. at $33.49 per share. 798,435
02/27/2021 Sally Susman
Executive Vice President
45,587   Derivative/Non-derivative trans. at $34.64 per share. 1,579,133
02/27/2021 Sally Susman
Executive Vice President
14,004   Derivative/Non-derivative trans. at $33.49 per share. 468,993
02/27/2021 Albert Bourla
Chairman & CEO; Director
34,191   Derivative/Non-derivative trans. at $34.64 per share. 1,184,376
02/27/2021 Albert Bourla
Chairman & CEO; Director
9,664   Derivative/Non-derivative trans. at $33.49 per share. 323,647
02/27/2021 Douglas M. Lankler
Executive Vice President
34,191   Derivative/Non-derivative trans. at $34.64 per share. 1,184,376
02/27/2021 Douglas M. Lankler
Executive Vice President
9,664   Derivative/Non-derivative trans. at $33.49 per share. 323,647
02/27/2021 Rady A. Johnson
Executive Vice President
15,955   Derivative/Non-derivative trans. at $34.64 per share. 552,681
02/27/2021 Rady A. Johnson
Executive Vice President
4,510   Derivative/Non-derivative trans. at $33.49 per share. 151,039
02/27/2021 Angela Hwang
Group President
6,268   Derivative/Non-derivative trans. at $34.64 per share. 217,123
02/27/2021 Angela Hwang
Group President
1,772   Derivative/Non-derivative trans. at $33.49 per share. 59,344
02/27/2021 William R. Carapezzi
Executive Vice President
13,676   Derivative/Non-derivative trans. at $34.64 per share. 473,736
02/27/2021 William R. Carapezzi
Executive Vice President
2,985   Derivative/Non-derivative trans. at $33.49 per share. 99,967
02/27/2021 Jennifer B. Damico
SVP & Controller
6,268   Derivative/Non-derivative trans. at $34.64 per share. 217,123
02/27/2021 Jennifer B. Damico
SVP & Controller
1,229   Derivative/Non-derivative trans. at $33.49 per share. 41,159
02/27/2021 Frank A. D'Amelio
Executive Vice President
152,785   Derivative/Non-derivative trans. at $22.35 per share. 3,414,744
02/27/2021 John D. Young
Group President
129,419   Derivative/Non-derivative trans. at $22.35 per share. 2,892,514
02/27/2021 Alexander Roderick MacKenzie
Executive Vice President
29,838   Derivative/Non-derivative trans. at $22.35 per share. 666,879
02/27/2021 Sally Susman
Executive Vice President
71,899   Derivative/Non-derivative trans. at $22.35 per share. 1,606,942
02/27/2021 Albert Bourla
Chairman & CEO; Director
53,925   Derivative/Non-derivative trans. at $22.35 per share. 1,205,223
02/27/2021 Douglas M. Lankler
Executive Vice President
53,925   Derivative/Non-derivative trans. at $22.35 per share. 1,205,223
02/27/2021 Rady A. Johnson
Executive Vice President
25,165   Derivative/Non-derivative trans. at $22.35 per share. 562,437
02/27/2021 Angela Hwang
Group President
9,886   Derivative/Non-derivative trans. at $22.35 per share. 220,952
02/27/2021 William R. Carapezzi
Executive Vice President
21,570   Derivative/Non-derivative trans. at $22.35 per share. 482,089
02/27/2021 Jennifer B. Damico
SVP & Controller
9,886   Derivative/Non-derivative trans. at $22.35 per share. 220,952
02/25/2021 Frank A. D'Amelio
Executive Vice President
105,707   Derivative/Non-derivative trans. at $34.76 per share. 3,674,375
02/25/2021 Frank A. D'Amelio
Executive Vice President
28,221   Derivative/Non-derivative trans. at $33.82 per share. 954,434
02/25/2021 John D. Young
Group President
105,707   Derivative/Non-derivative trans. at $34.76 per share. 3,674,375
02/25/2021 John D. Young
Group President
28,221   Derivative/Non-derivative trans. at $33.82 per share. 954,434
02/25/2021 Alexander Roderick MacKenzie
Executive Vice President
14,227   Derivative/Non-derivative trans. at $33.82 per share. 481,157
02/25/2021 Mikael Dolsten
President R&D
28,271   Derivative/Non-derivative trans. at $33.82 per share. 956,125
02/25/2021 Mikael Dolsten
President R&D
28,271   Derivative/Non-derivative trans. at $33.82 per share. 956,125
02/25/2021 Sally Susman
Executive Vice President
52,853   Derivative/Non-derivative trans. at $34.76 per share. 1,837,170
02/25/2021 Sally Susman
Executive Vice President
15,335   Derivative/Non-derivative trans. at $33.82 per share. 518,629
02/25/2021 Albert Bourla
Chairman & CEO; Director
105,707   Derivative/Non-derivative trans. at $34.76 per share. 3,674,375
02/25/2021 Albert Bourla
Chairman & CEO; Director
28,221   Derivative/Non-derivative trans. at $33.82 per share. 954,434
02/25/2021 Douglas M. Lankler
Executive Vice President
64,599   Derivative/Non-derivative trans. at $34.76 per share. 2,245,461
02/25/2021 Douglas M. Lankler
Executive Vice President
17,246   Derivative/Non-derivative trans. at $33.82 per share. 583,259
02/25/2021 Rady A. Johnson
Executive Vice President
24,371   Derivative/Non-derivative trans. at $34.76 per share. 847,135
02/25/2021 Rady A. Johnson
Executive Vice President
6,422   Derivative/Non-derivative trans. at $33.82 per share. 217,192
02/25/2021 Angela Hwang
Group President
14,682   Derivative/Non-derivative trans. at $34.76 per share. 510,346
02/25/2021 Angela Hwang
Group President
3,920   Derivative/Non-derivative trans. at $33.82 per share. 132,574
02/25/2021 William R. Carapezzi
Executive Vice President
17,618   Derivative/Non-derivative trans. at $34.76 per share. 612,401
02/25/2021 William R. Carapezzi
Executive Vice President
2,983   Derivative/Non-derivative trans. at $33.82 per share. 100,885
02/25/2021 Payal Sahni
Executive Vice President
6,460   Derivative/Non-derivative trans. at $34.76 per share. 224,549
02/25/2021 Payal Sahni
Executive Vice President
1,197   Derivative/Non-derivative trans. at $33.82 per share. 40,482
02/25/2021 Jennifer B. Damico
SVP & Controller
8,075   Derivative/Non-derivative trans. at $34.76 per share. 280,687
02/25/2021 Jennifer B. Damico
SVP & Controller
1,496   Derivative/Non-derivative trans. at $33.82 per share. 50,594
02/25/2021 Frank A. D'Amelio
Executive Vice President
163,334   Derivative/Non-derivative trans. at $22.89 per share. 3,738,715
02/25/2021 John D. Young
Group President
163,334   Derivative/Non-derivative trans. at $22.89 per share. 3,738,715
02/25/2021 Sally Susman
Executive Vice President
81,667   Derivative/Non-derivative trans. at $22.89 per share. 1,869,357
02/25/2021 Albert Bourla
Chairman & CEO; Director
163,334   Derivative/Non-derivative trans. at $22.86 per share. 3,733,815
02/25/2021 Douglas M. Lankler
Executive Vice President
99,816   Derivative/Non-derivative trans. at $22.89 per share. 2,284,788
02/25/2021 Rady A. Johnson
Executive Vice President
37,658   Derivative/Non-derivative trans. at $22.89 per share. 861,991
02/25/2021 Angela Hwang
Group President
22,686   Derivative/Non-derivative trans. at $22.89 per share. 519,282
02/25/2021 William R. Carapezzi
Executive Vice President
27,222   Derivative/Non-derivative trans. at $22.89 per share. 623,111
02/25/2021 Payal Sahni
Executive Vice President
9,982   Derivative/Non-derivative trans. at $22.89 per share. 228,487
02/25/2021 Jennifer B. Damico
SVP & Controller
12,477   Derivative/Non-derivative trans. at $22.89 per share. 285,598
02/25/2021 Alexander Roderick MacKenzie
Executive Vice President
26,732   Award at $0 per share. 0
02/25/2021 Jennifer B. Damico
SVP & Controller
3,649   Award at $0 per share. 0
02/22/2021 William R. Carapezzi
Executive Vice President
1,410   Derivative/Non-derivative trans. at $34.26 per share. 48,306
02/22/2021 Payal Sahni
Executive Vice President
1,172   Derivative/Non-derivative trans. at $34.26 per share. 40,152
02/22/2021 Jennifer B. Damico
SVP & Controller
884   Derivative/Non-derivative trans. at $34.26 per share. 30,285
01/31/2021 Lidia L. Fonseca
Executive Vice President
6,749   Derivative/Non-derivative trans. at $35.9 per share. 242,289
12/29/2020 John D. Young
Group President
10,607   Derivative/Non-derivative trans. at $37.05 per share. 392,989
12/16/2020 Rady A. Johnson
Executive Vice President
661   Gift at $0 per share. 0
12/16/2020 Angela Hwang
Group President
12,970   490,784
11/09/2020 Sally Susman
Executive Vice President
43,662   Disposition at $41.94 per share. 1,831,184
11/09/2020 Albert Bourla
Chairman & CEO; Director
132,508   Disposition at $41.94 per share. 5,557,385
08/06/2020 Ronald E. Blaylock
Director
1,000   Acquisition at $38.62 per share. 38,620
08/06/2020 Ronald E. Blaylock
Director
1,000   Acquisition at $38.69 per share. 38,690
08/06/2020 Ronald E. Blaylock
Director
1,500   Acquisition at $38.51 per share. 57,765
08/06/2020 Ronald E. Blaylock
Director
2,500   Acquisition at $38.56 per share. 96,400
08/06/2020 Ronald E. Blaylock
Director
3,000   Acquisition at $38.55 per share. 115,650
08/06/2020 Ronald E. Blaylock
Director
4,000   Acquisition at $38.49 per share. 153,960
06/05/2020 Jennifer B. Damico
SVP & Controller
2,181   Disposition at $36.13 per share. 78,799
05/18/2020 Mikael Dolsten
President R&D
24,242   Disposition at $37.79 per share. 916,105
05/18/2020 Mikael Dolsten
President R&D
17,357   Disposition at $37.78 per share. 655,747
05/18/2020 Mikael Dolsten
President R&D
16,840   Disposition at $37.8 per share. 636,552
05/18/2020 Mikael Dolsten
President R&D
14,727   Disposition at $37.77 per share. 556,238
05/18/2020 Mikael Dolsten
President R&D
9,700   Disposition at $37.75 per share. 366,175
05/18/2020 Mikael Dolsten
President R&D
6,470   Disposition at $37.81 per share. 244,630
05/18/2020 Mikael Dolsten
President R&D
5,517   Disposition at $37.76 per share. 208,321
05/18/2020 Mikael Dolsten
President R&D
500   Disposition at $37.82 per share. 18,910
/news/latest/company/us/pfe

MarketWatch News on PFE

  1. Johnson & Johnson vaccine should get blood-clot warning, European agency says

    10:27 a.m. Today

    - Steve Goldstein

  2. How Biogen Stock Could Rise 85%. Two Drugs Are Critical.

    10:03 a.m. April 19, 2021

    - Josh Nathan-Kazis

  3. J&J’s Vaccine Pause Could Have Ripple Effects for the World

    7:54 a.m. April 19, 2021

    - Josh Nathan-Kazis

  4. Futures Fall After Bitcoin Plunge

    6:21 p.m. April 18, 2021

  5. Half of all adults in U.S. have received at least one COVID-19 shot

    4:30 p.m. April 18, 2021

    - Associated Press

  6. Loading more headlines...
/news/nonmarketwatch/company/us/pfe

Other News on PFE

  1. Do J&J and AstraZeneca Vaccines Cause Blood Clots, and What Are the Symptoms?

    12:56 p.m. Today

    - Brianna Abbott

  2. Ocugen’s Outlook Is Still Very Bleak

    12:27 p.m. Today

    - InvestorPlace.com

  3. J&J’s Covid-19 Vaccine Adds $100 Million to Quarterly Sales

    11:11 a.m. Today

    - Peter Loftus

  4. Emergent (EBS) Bayview Unit Operation on Hold for FDA Probe

    10:18 a.m. Today

    - Zacks.com

  5. China set to approve BioNTech vaccine in June - Bloomberg

    10:14 a.m. Today

    - Seeking Alpha

  6. Pfizer (PFE)/ BioNTech to Supply Extra Comirnaty Doses to EU

    7:50 a.m. Today

    - Zacks.com

  7. Is It Too Late to Buy Moderna After Its 40% Gain?

    6:15 a.m. Today

    - Motley Fool

  8. 10 Words From Pfizer's CEO That Could Mean $10 Billion in Higher Vaccine Sales

    5:55 a.m. Today

    - Motley Fool

  9. A Covid-19 Lesson From Countries With Rapid Vaccine Rollouts

    5:30 a.m. Today

    - Jason Douglas

  10. Tax Bills May Go Up for Big Companies. It Will Be Hard to Tell How Much.

    5:30 a.m. Today

    - Mark Maurer

  11. Pfizer (PFE) Gains As Market Dips: What You Should Know

    5:45 p.m. April 19, 2021

    - Zacks.com

  12. I Got My Jab, Here's What Happened, And A Look At Vaccine Stocks

    5:14 p.m. April 19, 2021

    - Seeking Alpha

  13. What Does J&J's Pause Mean for Investors?

    9:05 a.m. April 19, 2021

    - Motley Fool

  14. 2 REITs That Could Double In The Recovery

    8:25 a.m. April 19, 2021

    - Seeking Alpha

  15. Wall Street Breakfast: Rev Up The Earnings

    7:06 a.m. April 19, 2021

    - Seeking Alpha

  16. Post Covid-19, Don’t Forget About Healthcare Stocks

    7:03 a.m. April 19, 2021

    - Charley Grant

  17. Pfizer (PFE) Gets a Buy Rating from Mizuho Securities

    5:04 a.m. April 19, 2021

    - SmarterAnalyst

  18. Loading more headlines...

At a Glance

Pfizer Inc.

235 East 42nd Street

New York, New York 10017-5755

Phone

1 2127332323

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$41.91B

Net Income

$6.99B

Employees

78,500

/news/pressrelease/company/us/pfe

Press Releases on PFE

  1. Antidepressant Drugs Market Industry Analysis, Market Size, Trends, Share and Forecast 2027

    10:41 a.m. Today

    - Market Insight Reports

  2. Global MEK Inhibitors Market Outlook, Industry Analysis and Prospect 2021

    9:51 a.m. Today

    - Heraldkeepers

  3. Global Hairy Cell Leukemia Drugs Market Outlook, Industry Analysis and Prospect 2021

    9:51 a.m. Today

    - Heraldkeepers

  4. New Report: Global Migraine Drugs Market 2019 Size, Growth Analysis Report, Forecast to 2025

    9:05 a.m. Today

    - Market Insight Reports

  5. The Importance of Alternative Healthcare Options Grows in the Midst of the Pandemic

    9:00 a.m. Today

    - PR Newswire - PRF

  6. Global Celecoxib Market Outlook, Industry Analysis and Prospect 2021

    8:39 a.m. Today

    - Heraldkeepers

  7. Loading more headlines...
Link to MarketWatch's Slice.